文献速递MDS 与骨髓增殖性肿瘤白血病

治疗相关慢性髓单核细胞白血病(CMML):与原发性CMML在分子、细胞遗传学和临床上的区别

Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
PubMed 文献 · Am J Hematol · 2017-11-03

在497例CMML患者队列中,9%诊断治疗相关CMML(t-CMML),发生于化疗和/或放疗后约7年。t-CMML与原发性CMML相比LDH更高、核型异常更频繁且高危细胞遗传学分层比例更高,基因突变分布无差异。t-CMML中位OS 10.9 vs 26个月、中位LFS 50 vs 127个月,独立不良影响OS(P=.0001,HR 2.1,95%CI 1.4-3.0)。

要点

  • 497例CMML队列中9%为t-CMML,发生于化疗和/或放疗后约7年。
  • t-CMML较原发CMML的LDH更高、核型异常更频繁、高危细胞遗传学分层比例更高。
  • t-CMML中位OS 10.9 vs 26个月、中位LFS 50 vs 127个月,独立不良影响OS。

核心结论

  • t-CMML具有独特遗传学特征和独立不良预后影响,作者认为应将其作为CMML和t-MN分类方案中的独立实体。

研究设计与样本

  • 大型(n=497)CMML患者队列,包含分子和细胞遗传学信息。
  • t-CMML诊断标准为既往化疗和/或放疗后发生的CMML,占9%。

主要发现

  • t-CMML发生于化疗和/或放疗后约7年。
  • t-CMML较原发CMML的LDH水平更高、核型异常频率更高、高危细胞遗传学分层比例更高。
  • 基因突变分布无差异;平衡染色体易位、11q23异常(1%)和Tp53突变(<2%)不常见。
  • 分子整合CMML预后模型对t-CMML风险分层无效;去甲基化药物治疗反应差,无完全缓解。
  • t-CMML中位OS 10.9 vs 原发CMML 26个月,中位LFS 50 vs 127个月;t-CMML独立不良影响OS(P=.0001,HR 2.1,95%CI 1.4-3.0)。

关键数值与推荐

  • t-CMML独立不良影响OS(P=.0001,HR 2.1,95%CI 1.4-3.0)。
  • 在Mayo分子模型背景下预后影响保留(P=.001,HR 2.4,95%CI 1.5-3.7)。
  • 在GFM预后模型背景下预后影响保留(P<.0001,HR 2.15,95%CI 1.5-3.7)。

临床怎么用

  • 作者认为t-CMML应作为CMML和t-MN分类方案中的独立实体。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy related myeloid neoplasms (t-MN) including therapy related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML) are associated with aggressive disease biologies and poor outcomes. In this large (n = 497) and informative (inclusive of molecular and cytogenetic information) chronic myelomonocytic leukemia (CMML) patient cohort, we demonstrate key biological insights and an independent prognostic impact for t-CMML. T-CMML was diagnosed in 9% of patients and occurred approximately 7 years after exposure to prior chemotherapy and/or radiation therapy. In comparison to de novo CMML, t-CMML patients had higher LDH levels, higher frequency of karyotypic abnormalities and had higher risk cytogenetic stratification. There were no differences in the distribution of gene mutations and unlike t-MDS/AML, balanced chromosomal translocations, abnormalities of chromosome 11q23 (1%) and Tp53 mutations (<2%) were uncommon. Molecularly integrated CMML prognostic models were not effective in risk stratifying t-CMML patients and responses to hypomethylating agents were dismal with no complete responses. Median overall (OS) and leukemia free survival (LFS) was shorter for t-CMML in comparison to d-CMML (Median OS 10.9 vs 26 months and median LFS 50 vs 127 months) and t-CMML independently and adversely impacted OS (P = .0001 HR 2.1 95% CI 1.4-3.0). This prognostic impact was retained in the context of the Mayo Molecular Model (P = .001, HR 2.4, 95% CI 1.5-3.7) and the GFM prognostic model (P < .0001, HR 2.15, 95% CI 1.5-3.7). In summary, we highlight the unique genetics and independent prognostic impact of t-CMML, warranting its inclusion as a separate entity in the classification schema for both CMML and t-MN.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Patnaik MM, Vallapureddy R, Yalniz FF, et al. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2017. PMID: 29023992. doi:10.1002/ajh.24939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。